CellSeed Inc. (TYO:7776)

Market Cap	17.85B
Revenue (ttm)	161.00M
Net Income (ttm)	-914.00M
Shares Out	34.67M
EPS (ttm)	-53.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	601,800
Average Volume	1,161,190
Open	515.00
Previous Close	515.00
Day's Range	508.00 - 518.00
52-Week Range	223.00 - 1,160.00
Beta	0.80
RSI	45.73
Earnings Date	Aug 13, 2025

About CellSeed

CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 44
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 7776

Financial Performance

In 2021, CellSeed's revenue was 161.00 million, a decrease of -19.10% compared to the previous year's 199.00 million. Losses were -914.00 million, 16.7% more than in 2020.